ESEthan Sukumar Sen

Ethan Sukumar Sen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ethan Sukumar Sen has a total of 268 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Variation in Biologic and Targeted Synthetic DMARD Access for Juvenile Idiopathic Arthritis: Insights from a National UK Survey

    by Samantha Cooray, Kalindi Rajani, Sandrine Compeyrot-Lacassagne, Ethan S. Sen, Catriona Anderson, Andrew Fell, Dearbhla McKenna, Clara Danielsen, Mario Cortina-Borja, Coziana Ciurtin, et al.

    Background: Biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have transformed outcomes for juvenile idiopathic arthritis (JIA). Despite this, there is limited contemporary understanding of real-world access to these therapies across the UK, where commissioning pathways, service configuration, and age- and specialty-based prescribing rules contribute to variations in care.Methods: We conducted a national cross-sectional survey of multidisciplinary teams (MDTs) across UK paediatric and adolescent/adult rheumatology centres to characterise real-world access to b/tsDMARDs for JIA. The survey captured MDT composition, commissioned treatment pathways, dosing constraints, and other barriers to access. Treatment patterns were analysed by JIA subtype, UK nation, age group, and specialty pathway, with quantitative visualisation and thematic analysis of free-text responses.Findings: Responses were received from 13 out of 17 tertiary/quaternary specialist centres across all four UK nations, representing 123 multidisciplinary professionals. Access to b/tsDMARDs for JIA varied substantially by region, disease subtype, age, and specialty pathway. Adalimumab was used first line for most JIA subtypes and universally for JIA-associated uveitis. Tocilizumab was the most commonly used second-line agent across multiple JIA subtypes, including polyarticular disease and uveitis, and was widely used first- and second-line for systemic JIA (sJIA/Still’s. sJIA was otherwise predominantly treated with the interleukin-1 inhibitor anakinra, particularly in the context of macrophage activation syndrome (MAS). Access to canakinumab for sJIA was restricted to Scotland and Northern Ireland, despite trial evidence supporting its use. In England and Wales, adalimumab remains the only commissioned therapy for JIA-associated uveitis; paediatric access to anti-IL-17 agents for enthesitis-related arthritis (ERA) was limited. Newer agents, higher biologic dosing, and broader therapeutic choice were more readily accessed through dermatology or gastroenterology pathways, particularly for psoriatic JIA and inflammatory bowel disease–associated arthritis. Adolescent and adult services reported wider access to biologics, sometimes requiring diagnostic reclassification to adult inflammatory arthritides. Biosimilars were universally adopted, although specialist rheumatology pharmacy support was not consistently available. Hematopoietic stem cell transplantation (HSCT) and combination biologic therapy was reserved for refractory disease, MAS, or severe extra-articular involvement.Interpretation: Access to effective b/tsDMARD therapies for JIA in the UK is highly variable and frequently determined by commissioning rules, age thresholds, and specialty silos rather than clinical need. National alignment of commissioning and treatment pathways across UK nations and across paediatric and adult services is urgently required to ensure equitable, timely access to evidence-based therapies for children and young people with JIA.

  • Cytokine Storm Syndrome Associated with Hemorrhagic Fever and Other Viruses

    by Ethan S. Sen, A. V. Ramanan

    A wide variety of infections can trigger cytokine storm syndromes including those caused by bacteria, viruses, fungi and parasites. The most frequent viral trigger is Epstein–. Barr virus which is covered in Chapter 16. CSS associated with COVID-19 is also discussed separately (Chapter 22). This chapter will focus on other viruses including the hemorrhagic fever viruses, influenza, parainfluenza, adenovirus, parvovirus, hepatitis viruses, measles, mumps, rubella, enterovirus, parechovirus, rotavirus, human metapneumovirus and human T-lymphotropic virus. The published literature consists of many single case reports and moderate-sized case series reporting CSS, in most circumstances meeting the 2004 diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH). There is no published clinical trial evidence specifically for management of HLH associated with these viruses. In some situations, patients received supportive therapy and blood product transfusions only but in most cases, they were treated with one or more of intravenous corticosteroids, intravenous immunoglobulin and/or etoposide. These were successful in many patients although in significant numbers progression of infection to CSS was associated with mortality.


  • Open Access

    SARS-CoV-2 vaccinations in children and adolescents with rheumatic diseases

    by Ethan S Sen, Dalila Julandani, Athimalaipet V Ramanan

    Ethan S Sen, Dalila Julandani, Athimalaipet V Ramanan; SARS-CoV-2 vaccinations in children and adolescents with rheumatic diseases, Rheumatology, , keac431, htt


  • Response to First Course of Intensified Immunosuppression in Genetically Stratified Steroid Resistant Nephrotic Syndrome

    by Anna E. Mason, Ethan S. Sen, Agnieszka Bierzynska, Elizabeth Colby, Maryam Afzal, Guillaume Dorval, Ania B. Koziell, Maggie Williams, Olivia Boyer, Gavin I. Welsh, et al.

    Background and objectives: Intensified immunosuppression in steroid-resistant nephrotic syndrome is broadly applied, with disparate outcomes. This review of patients from the United Kingdom National Study of Nephrotic Syndrome cohort aimed to improve disease stratification by determining, in comprehensively genetically screened patients with steroid-resistant nephrotic syndrome, if there is an association between response to initial intensified immunosuppression and disease progression and/or post-transplant recurrence. Design, setting, participants, & measurements: Pediatric patients with steroid-resistant nephrotic syndrome were recruited via the UK National Registry of Rare Kidney Diseases. All patients were whole-genome sequenced, whole-exome sequenced, or steroid-resistant nephrotic syndrome gene-panel sequenced. Complete response or partial response within 6 months of starting intensified immunosuppression was ascertained using laboratory data. Response to intensified immunosuppression and outcomes were analyzed according to genetic testing results, pattern of steroid resistance, and first biopsy findings. Results: Of 271 patients, 178 (92 males, median onset age 4.7 years) received intensified immunosuppression with response available. A total of 4% of patients with monogenic disease showed complete response, compared with 25% of genetic-testing-negative patients (P=0.02). None of the former recurred post-transplantation. In genetic-testing-negative patients, 97% with complete response to first intensified immunosuppression did not progress, whereas 44% of nonresponders developed kidney failure with 73% recurrence post-transplant. Secondary steroid resistance had a higher complete response rate than primary/presumed resistance (43% versus 23%; P=0.001). The highest complete response rate in secondary steroid resistance was to rituximab (64%). Biopsy results showed no correlation with intensified immunosuppression response or outcome. Conclusions: Patients with monogenic steroid-resistant nephrotic syndrome had a poor therapeutic response and no post-transplant recurrence. In genetic-testing-negative patients, there was an association between response to first intensified immunosuppression and long-term outcome. Patients with complete response rarely progressed to kidney failure, whereas nonresponders had poor kidney survival and a high post-transplant recurrence rate. Patients with secondary steroid resistance were more likely to respond, particularly to rituximab.


  • Open Access

    Efficacy of pamidronate in children with chronic non-bacterial osteitis using whole body MRI as a marker of disease activity

    by C. S. Bhat, M. Roderick, E. S. Sen, A. Finn, A. V. Ramanan

    To study the response to pamidronate using whole body magnetic resonance imaging (WB-MRI) in children with chronic non-bacterial osteitis (CNO) in a tertiary health centre. The medical records of children under the age of sixteen with a diagnosis of chronic non-bacterial osteitis between 2005 and 2018 were reviewed. All those who were treated with pamidronate were included and relevant data was collected. Response to therapy was determined based on the status of lesions on WB- MRI. Forty six patients were included in the study. Pre- and post-treatment WB-MRI was available in forty patients. Cumulative lesions pre-treatment were 150 and reduced to 45 (30%) post-treatment. Seventeen patients (42.5%) had a good response with complete resolution of all lesions and nine patients (22.5%) worsened during or following treatment with pamidronate. Vertebral disease had a good response and 82.3% of the lesions resolved completely. Our study describes the experience with pamidronate in a tertiary health centre using WB-MRI as a marker of disease activity. Pamidronate was well tolerated in our cohort and treatment response was fairly good. 1. Bisphosphonates can be used in the treatment of CNO when response to NSAIDs is suboptimal. 2. In the presence of spinal or mandibular lesions bisphosphonates were used as first line. 3. Treatment was escalated to a TNF blocker when response to bisphosphonates was suboptimal.


  • Open Access

    FRI0541 HIGHLY ELEVATED FERRITIN LEVELS ARE ASSOCIATED WITH HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS/MACROPHAGE ACTIVATION SYNDROME – ARE WE MISSING TREATABLE DIAGNOSES? A RETROSPECTIVE SERVICE EVALUATION OF DIAGNOSIS IN PATIENTS WITH FERRITIN >10,000 MICROGRAM/L

    by Ethan Sen, Beverley Almeida, Louise Moran, Charlene Foley, Nagla Abdelrahman, Rosie Close, Ema-Louise Long, Joshua Bennett, Jason Palman, Catriona Anderson, et al.

    Background Haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) is a hyperinflammatory syndrome potentially leading to critical illness. Early treatment reduces mortality but diagnosis requires a high index of suspicion. Highly elevated ferritin levels (HEF) >10,000 μg/L are highly specific for HLH/MAS [1] and should prompt consideration of hyperinflammation. Diagnostic guidelines for HLH, requiring the presence of ≥5/8 criteria [2], and classification criteria for MAS complicating systemic juvenile idiopathic arthritis (sJIA) have been published [3]. Objectives To assess recognition of HLH/MAS in a paediatric population with HEF. Methods This retrospective study was conducted at 11 centres under local service evaluation permissions. Biochemistry databases identified patients ≤16 years with serum ferritin >10,000 μg/L during a 3-year period. Each case was assessed against the 2004 HLH criteria and, for patients with sJIA, the 2016 MAS criteria. Due to limited access to some of the laboratory tests, previously-published modified HLH criteria using a threshold of ≥4/5 (excluding tissue haemophagocytosis, decreased natural killer cell function, increased soluble interleukin-2 receptor) were also applied to all patients [4]. Results 153 patients (55.6% male) were identified. Patient diagnoses included: infections (29.4%), rheumatological (17.0%) and malignancies (17.0%). A diagnosis of HLH/MAS was made by the treating clinical team in 39.9% and considered in a further 16.3%. Using all available data, 30/153 (19.6%) met ≥5/8 criteria and 93.3% of these patients were diagnosed with HLH/MAS by the treating team. 56 (36.6%) met ≥4/5 criteria and 33 (58.9%) of these were diagnosed with HLH/MAS by clinicians. HLH/MAS was not documented as being considered in the differential in 23.2%. Of 23 patients with sJIA, 82.6% met MAS classification criteria and 89.5% of these were diagnosed with MAS by the treating clinicians. Overall mortality was 32.7% (50/153) and was 27.9% (17/61) in patients diagnosed with HLH/MAS during their admission. Conclusion Although HEF is highly specific for HLH/MAS, the diagnosis was only made or considered in just over half of paediatric patients with this laboratory result. Increased awareness of this potentially-lethal condition is likely to lead to earlier treatment and reduced mortality. References [1] Allen CE, et al. 2008;50:1227-35. [2] Henter JI, et al. 2007;48:124-31. [3] Ravelli A, et al. 2016;75:481-9. [4] Davì S, et al. 2014;66:2871-80. Disclosure of Interests Ethan Sen: None declared, Beverley Almeida: None declared, Louise Moran: None declared, Charlene Foley: None declared, Nagla Abdelrahman: None declared, Rosie Close: None declared, Ema-Louise Long: None declared, Joshua Bennett: None declared, Jason Palman: None declared, Catriona Anderson: None declared, Kirsty McLellan: None declared, Samundeeswari Deepak: None declared, Kathy Gallagher: None declared, Peter Bale: None declared, Kamran Mahmood: None declared, Clare Pain: None declared, Flora McErlane: None declared, Athimalaipet Ramanan Consultant for: AbbVie, UCB, Sobi, Eli Lilly, Speakers bureau: Speaker fees/honoraria from Abbvie, SOBI, Eli Lilly and UCB, Speakers bureau: AbbVie, UCB, Sobi, Eli Lilly, Rachel Tattersall: None declared


  • R06 Highly elevated ferritin levels are associated with haemophagocytic lymphohistiocytosis/macrophage activation syndrome: are we missing treatable diagnoses? A retrospective service evaluation of diagnosis in patients with ferritin >10,000 μg/L

    by Ethan S Sen, Beverley Almeida, Louise Moran, Charlene Foley, Rosie Close, Ema-Louise Long, Joshua Bennett, Jason Palman, Catriona M Anderson, Kirsty McLellan, et al.

    Background: Haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) is a hyperinflammatory syndrome which can complicate sepsis, malignancy or autoimmune disease, potentially leading to critical illness and death. Early diagnosis and treatment reduce mortality but diagnosis requires a high index of suspicion and correct interpretation of laboratory results. Highly elevated ferritin levels (HEF) >10,000 μg/L are highly specific for HLH/MAS and should prompt consideration/exclusion of hyperinflammation. Diagnostic guidelines for HLH were published in 2004 requiring the presence of ⩾ 5/8 criteria and consensus classification criteria for MAS complicating systemic juvenile idiopathic arthritis (sJIA) were published in 2016. The aim of this study was to assess recognition...